175 related articles for article (PubMed ID: 11803068)
1. The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant.
Scanlen M; Paweska JT; Verschoor JA; van Dijk AA
Vaccine; 2002 Jan; 20(7-8):1079-88. PubMed ID: 11803068
[TBL] [Abstract][Full Text] [Related]
2. Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
Roy P; Bishop DH; Howard S; Aitchison H; Erasmus B
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2053-7. PubMed ID: 8811002
[TBL] [Abstract][Full Text] [Related]
3. Immunization with VP2 is sufficient for protection against lethal challenge with African horsesickness virus Type 4.
Stone-Marschat MA; Moss SR; Burrage TG; Barber ML; Roy P; Laegreid WW
Virology; 1996 Jun; 220(1):219-22. PubMed ID: 8659117
[TBL] [Abstract][Full Text] [Related]
4. Protein aggregation complicates the development of baculovirus-expressed African horsesickness virus serotype 5 VP2 subunit vaccines.
du Plessis M; Cloete M; Aitchison H; Van Dijk AA
Onderstepoort J Vet Res; 1998 Dec; 65(4):321-9. PubMed ID: 10192846
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
[TBL] [Abstract][Full Text] [Related]
6. A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model.
Aksular M; Calvo-Pinilla E; Marín-López A; Ortego J; Chambers AC; King LA; Castillo-Olivares J
Vaccine; 2018 Nov; 36(46):7003-7010. PubMed ID: 30309744
[TBL] [Abstract][Full Text] [Related]
7. The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.
Calvo-Pinilla E; Gubbins S; Mertens P; Ortego J; Castillo-Olivares J
Antiviral Res; 2018 Jun; 154():132-139. PubMed ID: 29678552
[TBL] [Abstract][Full Text] [Related]
8. Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
Martínez-Torrecuadrada JL; Díaz-Laviada M; Roy P; Sánchez C; Vela C; Sánchez-Vizcaíno JM; Casal JI
J Gen Virol; 1996 Jun; 77 ( Pt 6)():1211-21. PubMed ID: 8683209
[TBL] [Abstract][Full Text] [Related]
9. VP2 Exchange and NS3/NS3a Deletion in African Horse Sickness Virus (AHSV) in Development of Disabled Infectious Single Animal Vaccine Candidates for AHSV.
van de Water SG; van Gennip RG; Potgieter CA; Wright IM; van Rijn PA
J Virol; 2015 Sep; 89(17):8764-72. PubMed ID: 26063433
[TBL] [Abstract][Full Text] [Related]
10. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus.
Guthrie AJ; Quan M; Lourens CW; Audonnet JC; Minke JM; Yao J; He L; Nordgren R; Gardner IA; Maclachlan NJ
Vaccine; 2009 Jul; 27(33):4434-8. PubMed ID: 19490959
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge.
Alberca B; Bachanek-Bankowska K; Cabana M; Calvo-Pinilla E; Viaplana E; Frost L; Gubbins S; Urniza A; Mertens P; Castillo-Olivares J
Vaccine; 2014 Jun; 32(29):3670-4. PubMed ID: 24837765
[TBL] [Abstract][Full Text] [Related]
12. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
El Garch H; Crafford JE; Amouyal P; Durand PY; Edlund Toulemonde C; Lemaitre L; Cozette V; Guthrie A; Minke JM
Vet Immunol Immunopathol; 2012 Sep; 149(1-2):76-85. PubMed ID: 22763149
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.
Kanai Y; van Rijn PA; Maris-Veldhuis M; Kaname Y; Athmaram TN; Roy P
Vaccine; 2014 Sep; 32(39):4932-7. PubMed ID: 25045805
[TBL] [Abstract][Full Text] [Related]
14. African horsesickness virus VP7 sub-unit vaccine protects mice against a lethal, heterologous serotype challenge.
Wade-Evans AM; Pullen L; Hamblin C; O'Hara R; Burroughs JN; Mertens PP
J Gen Virol; 1997 Jul; 78 ( Pt 7)():1611-6. PubMed ID: 9225037
[TBL] [Abstract][Full Text] [Related]
15. Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.
Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
Antiviral Res; 2015 Apr; 116():27-33. PubMed ID: 25643968
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization.
Martinez-Torrecuadrada JL; Iwata H; Venteo A; Casal I; Roy P
Virology; 1994 Jul; 202(1):348-59. PubMed ID: 8009847
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.
Calvo-Pinilla E; de la Poza F; Gubbins S; Mertens PP; Ortego J; Castillo-Olivares J
Virus Res; 2014 Feb; 180():23-30. PubMed ID: 24333835
[TBL] [Abstract][Full Text] [Related]
18. Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara.
Marín-López A; Barreiro-Piñeiro N; Utrilla-Trigo S; Barriales D; Benavente J; Nogales A; Martínez-Costas J; Ortego J; Calvo-Pinilla E
Vaccine; 2020 Jan; 38(4):882-889. PubMed ID: 31708178
[TBL] [Abstract][Full Text] [Related]
19. Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
Chiam R; Sharp E; Maan S; Rao S; Mertens P; Blacklaws B; Davis-Poynter N; Wood J; Castillo-Olivares J
PLoS One; 2009 Jun; 4(6):e5997. PubMed ID: 19543394
[TBL] [Abstract][Full Text] [Related]
20. African horse sickness virus (AHSV) with a deletion of 77 amino acids in NS3/NS3a protein is not virulent and a safe promising AHS Disabled Infectious Single Animal (DISA) vaccine platform.
van Rijn PA; Maris-Veldhuis MA; Potgieter CA; van Gennip RGP
Vaccine; 2018 Apr; 36(15):1925-1933. PubMed ID: 29525278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
